Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

"In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity," Ghobadi said. "For patients ...

Recent research has focused on understanding the role of specific proteins, particularly B-cell lymphoma 6 (BCL6), in the development and progression of this disease. BCL6 is a transcription ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

"In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity," Ghobadi said. "For patients ...

This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

The asset in question, an autologous CAR-T dubbed ASP2802 aimed at CD20-positive B-cell lymphomas, had been undergoing a phase 1 trial to determine a suitable dose for further studies as well as ...

In search of other potential players, the researchers scoured a national database of human tissue samples and noticed an abundance of BCL6 in muscle cells—a clue that it may play an important ...